CIPROTERONA SERVYCAL

Cyproterone Acetate 50 mg

Tablets

Sale under filed prescription

Made in Argentina

Any medicine having cyproterone acetate as its active ingredient may produce the effects mentioned below.

QUALI-QUANTITATIVE COMPOSITION:
Each tablet contains:

THERAPEUTIC ACTION:
ATC Classification: G03H A01
Antiandrogen.
Cyproterone acetate inhibits the action of male sex hormones (androgens) which, to a lesser extent, are also present in females. It also exerts a gestagenic and antigonadotrophic action. In male patients, treatment with cyproterone acetate reduces sexual drive and potency, and inhibits gonadal function.
These changes are reversible upon discontinuation of treatment.
Cyproterone acetate protects androgen dependent target organs, such as the prostate, against the effect of gonadal and/or adrenocortical androgens.
In women, hirsutism is diminished, but also androgen dependent loss of hair and elevated sebaceous gland function are reduced. During treatment, ovarian function is inhibited.

INDICATIONS:
Cyproterone acetate is indicated:

• For the antiandrogenic treatment of hormone-dependent inoperable prostatic carcinoma.
• To diminish the initial increase of male sex hormones in the treatment with LHRH agonists
• To preclude the effect of adrenocortical androgens in the treatment with LHRH agonists.
• For the treatment of severe signs of androgenization in women, such us excessive and pathological hair growth in the face and body (severe hirsutism) and marked hair loss to baldness (severe androgenic alopecia), usually associated with acne and/or seborrhea.
• For the reduction of drive in male sexual deviations.
• For the treatment of postmenopausal or hysterectomized women with cyproterone acetate as single agent.

PRESENTATION:
Ciproterona Servycal 50 mg x 50 tablets.

Store between 15ºC and 30ºC and protect from light